Deletions and missense mutations of EPM2A exacerbate unfolded protein response and apoptosis of neuronal cells induced by endoplasm reticulum stress

Human Molecular Genetics

Volumn 18, Issue 14, 2009, Pages 2622-2631

  Liu, Yan ^a   Wang, Yin ^a   Wu, Cindy ^b   Liu, Yang ^a   Zheng, Pan ^a,c  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^b THE OHIO STATE UNIVERSITY WEXNER MEDICAL CENTER   (United States)

^c UNIVERSITY OF MICHIGAN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 PHENYLBUTYRIC ACID; COMPLEMENTARY DNA; GENE PRODUCT; LAFORIN; PROTEIN EPM2A; THAPSIGARGIN; UNCLASSIFIED DRUG;

AGGRESOME; AMINO ACID SEQUENCE; APOPTOSIS; ARTICLE; CALCIUM CELL LEVEL; CONTROLLED STUDY; ENDOPLASMIC RETICULUM STRESS; EXON; GENE DELETION; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; MISSENSE MUTATION; MYOCLONUS EPILEPSY; NERVE CELL; NEUROPATHOLOGY; PRIORITY JOURNAL; PROTEIN FOLDING; PROTEIN LOCALIZATION; UBIQUITINATION; WILD TYPE;

ANIMALS; APOPTOSIS; CELL LINE; ENDOPLASMIC RETICULUM; HUMANS; LAFORA DISEASE; MICE; MUTATION; MUTATION, MISSENSE; NEURONS; NIH 3T3 CELLS; PROTEIN FOLDING; PROTEIN TYROSINE PHOSPHATASES, NON-RECEPTOR; SEQUENCE DELETION;

EID: 67649859658     PISSN: 09646906     EISSN: 14602083     Source Type: Journal    
DOI: 10.1093/hmg/ddp196     Document Type: Article

References (37)

1. Minassian, B.A. (2002) Progressive myoclonus epilepsy with polyglucosan bodies: Lafora disease. Adv. Neurol., 89, 199-210.
2. Sakai, M., Austin, J., Witmer, F. and Trueb, L. (1970) Studies in myoclonus epilepsy (Lafora body form). II. Polyglucosans in the systemic deposits of myoclonus epilepsy and in corpora amylacea. Neurology, 20, 160-176.
3. Gambetti, P., Di Mauro, S., Hirt, L. and Blume, R.P. (1971) Myoclonic epilepsy with lafora bodies. Some ultrastructural, histochemical, and biochemical aspects. Arch. Neurol., 25, 483-493.
4. Cavanagh, J.B. (1999) Corpora-amylacea and the family of polyglucosan diseases. Brain Res. Brain Res. Rev., 29, 265-295.
5. Minassian, B.A., Lee, J.R., Herbrick, J.A., Huizenga, J., Soder, S., Mungall, A.J., Dunham, I., Gardner, R., Fong, C.Y., Carpenter, S. et al. (1998) Mutations in a gene encoding a novel protein tyrosine phosphatase cause progressive myoclonus epilepsy. Nat. Genet., 20, 171-174.
6. Chan, E.M., Young, E.J., Ianzano, L., Munteanu, I., Zhao, X., Christopoulos, C.C., Avanzini, G., Elia, M., Ackerley, C.A., Jovic, N.J. et al. (2003) Mutations in NHLRC1 cause progressive myoclonus epilepsy. Nat. Genet., 35, 125-127.
7. Ganesh, S., Agarwala, K.L., Ueda, K., Akagi, T., Shoda, K., Usui, T., Hashikawa, T., Osada, H., Delgado-Escueta, A.V. and Yamakawa, K. (2000) Laforin, defective in the progressive myoclonus epilepsy of Lafora type, is a dual-specificity phosphatase associated with polyribosomes. Hum. Mol. Genet., 9, 2251-2261.
8. Gentry, M.S., Worby, C.A. and Dixon, J.E. (2005) Insights into Lafora disease: Malin is an E3 ubiquitin ligase that ubiquitinates and promotes the degradation of laforin. Proc. Natl Acad. Sci. USA, 102, 8501-8506.
9. Genton, P. (2007) Lafora's disease (EPM2). Rev. Neurol. (Paris), 163, 47-53.
10. Minassian, B.A., Ianzano, L., Meloche, M., Andermann, E., Rouleau, G.A., Delgado-Escueta, A.V. and Scherer, S.W. (2000) Mutation spectrum and predicted function of laforin in Lafora's progressive myoclonus epilepsy. Neurology, 55, 341-346.
11. Liu, R., Wang, L., Chen, C., Liu, Y., Zhou, P., Wang, Y., Wang, X., Turnbull, J., Minassian, B.A., Liu, Y. et al. (2008) Laforin negatively regulates cell cycle progression through glycogen synthase kinase 3(beta)-dependent mechanisms. Mol. Cell. Biol., 28, 7236-7244.
12. Liu, Y., Wang, Y., Wu, C., Liu, Y. and Zheng, P. (2006) Dimerization of Laforin is required for its optimal phosphatase activity, regulation of GSK3beta phosphorylation, and Wnt signaling. J. Biol. Chem., 281, 34768-34774.
13. Lohi, H., Ianzano, L., Zhao, X.C., Chan, E.M., Turnbull, J., Scherer, S.W., Ackerley, C.A. and Minassian, B.A. (2005) Novel glycogen synthase kinase 3 and ubiquitination pathways in progressive myoclonus epilepsy. Hum. Mol. Genet., 14, 2727-2736.
14. Wang, Y., Liu, Y., Wu, C., Zhang, H., Zheng, X., Zheng, Z., Geiger, T.L., Nuovo, G.J., Liu, Y. and Zheng, P. (2006) Epm2a suppresses tumor growth in an immunocompromised host by inhibiting Wnt signaling. Cancer Cell, 10, 179-190.
15. Tagliabracci, V.S., Turnbull, J., Wang, W., Girard, J.M., Zhao, X., Skurat, A.V., Delgado-Escueta, A.V., Minassian, B.A., Depaoli-Roach, A.A. and Roach, P.J. (2007) Laforin is a glycogen phosphatase, deficiency of which leads to elevated phosphorylation of glycogen in vivo. Proc. Natl Acad. Sci. USA, 104, 19262-19266.
16. Worby, C.A., Gentry, M.S. and Dixon, J.E. (2008) Malin decreases glycogen accumulation by promoting the degradation of protein targeting to glycogen (PTG). J. Biol. Chem., 283, 4069-4076.
17. Wang, Y., Liu, Y., Wu, C., McNally, B., Liu, Y. and Zheng, P. (2008) Laforin confers cancer resistance to energy deprivation-induced apoptosis. Cancer Res., 68, 4039-4044.
18. Chan, E.M., Andrade, D.M., Franceschetti, S. and Minassian, B. (2005) Progressive myoclonus epilepsies: EPM1, EPM2A, EPM2B. Adv. Neurol. 95, 47-57.
19. Delgado-Escueta, A.V., Ganesh, S. and Yamakawa, K. (2001) Advances in the genetics of progressive myoclonus epilepsy. Am. J. Med. Genet. 106, 129-138.
20. Ganesh, S., Puri, R., Singh, S., Mittal, S. and Dubey, D. (2006) Recent advances in the molecular basis of Lafora's progressive myoclonus epilepsy. J. Hum. Genet., 51, 1-8.
21. Vilchez, D., Ros, S., Cifuentes, D., Pujadas, L., Valles, J., Garcia-Fojeda, B., Criado-Garcia, O., Fernandez-Sanchez, E., Medrano-Fernandez, I., Dominguez, J. et al. (2007) Mechanism suppressing glycogen synthesis in neurons and its demise in progressive myoclonus epilepsy. Nat. Neurosci., 10, 1407-1413.
22. Solaz-Fuster, M.C., Gimeno-Alcaniz, J.V., Ros, S., Fernandez-Sanchez, M.E., Garcia-Fojeda, B., Criado Garcia, O., Vilchez, D., Dominguez, J., Garcia-Rocha, M., Sanchez-Piris, M. et al. (2008) Regulation of glycogen synthesis by the laforin-malin complex is modulated by the AMP-activated protein kinase pathway. Hum. Mol. Genet., 17, 667-678.
23. Wang, J., Stuckey, J.A., Wishart, M.J. and Dixon, J.E. (2002) A unique carbohydrate binding domain targets the lafora disease phosphatase to glycogen. J. Biol. Chem., 277, 2377-2380.
24. Dubey, D. and Ganesh, S. (2008) Modulation of functional properties of laforin phosphatase by alternative splicing reveals a novel mechanism for the EPM2A gene in Lafora progressive myoclonus epilepsy. Hum. Mol. Genet., 17, 3010-3020.
25. Ganesh, S., Delgado-Escueta, A.V., Sakamoto, T., Avila, M.R., Machado-Salas, J., Hoshii, Y., Akagi, T., Gomi, H., Suzuki, T., Amano, K. et al. (2002) Targeted disruption of the Epm2a gene causes formation of Lafora inclusion bodies, neurodegeneration, ataxia, myoclonus epilepsy and impaired behavioral response in mice. Hum. Mol. Genet., 11, 1251-1262.
26. Mittal, S., Dubey, D., Yamakawa, K. and Ganesh, S. (2007) Lafora disease proteins malin and laforin are recruited to aggresomes in response to proteasomal impairment. Hum. Mol. Genet., 16, 753-762.
27. Kim, I., Xu, W. and Reed, J.C. (2008) Cell death and endoplasmic reticulum stress: Disease relevance and therapeutic opportunities. Nat. Rev. Drug Discov., 7, 1013-1030.
28. Layfield, R., Cavey, J.R. and Lowe, J. (2003) Role of ubiquitin-mediated proteolysis in the pathogenesis of neurodegenerative disorders. Ageing Res. Rev., 2, 343-356.
29. Sherman, M.Y. and Goldberg, A.L. (2001) Cellular defenses against unfolded proteins: A cell biologist thinks about neurodegenerative diseases. Neuron, 29, 15-32.
30. Tveten, K., Holla, O.L., Ranheim, T., Berge, K.E., Leren, T.P. and Kulseth, M.A. (2007) 4-Phenylbutyrate restores the functionality of a misfolded mutant low-density lipoprotein receptor. FEBS J., 274 1881-1893.
31. Ozcan, U., Yilmaz, E., Ozcan, L., Furuhashi, M., Vaillancourt, E., Smith, R.O., Gorgun, C.Z. and Hotamisligil, G.S. (2006) Chemical chaperones reduce ER stress and restore glucose homeostasis in a mouse model of type 2 diabetes. Science, 313, 1137-1140.
32. Jiang, H.Y. and Wek, R.C. (2005) Phosphorylation of the alpha-subunit of the eukaryotic initiation factor-2 (eIF2alpha) reduces protein synthesis and enhances apoptosis in response to proteasome inhibition. J. Biol. Chem., 280, 14189-14202.
33. Chan, E.M., Ackerley, C.A., Lohi, H., Ianzano, L., Cortez, M.A., Shannon, P., Scherer, S.W. and Minassian, B.A. (2004) Laforin preferentially binds the neurotoxic starch-like polyglucosans, which form in its absence in progressive myoclonus epilepsy. Hum. Mol. Genet., 13, 1117-1129.
34. Tagliabracci, V.S., Girard, J.M., Segvich, D., Meyer, C., Turnbull, J., Zhao, X., Minassian, B.A., Depaoli-Roach, A.A. and Roach, P.J. (2008) Abnormal metabolism of glycogen phosphate as a cause for Lafora disease. J. Biol. Chem., 283, 33816-33825.
35. Minassian, B.A. (2001) Lafora's disease: Towards a clinical, pathologic, and molecular synthesis. Pediatr. Neurol., 25, 21-29.
36. Garyali, P., Siwach, P., Singh, P.K., Puri, R., Mittal, S., Sengupta, S., Parihar, R. and Ganesh, S. (2009) The malin-laforin complex suppresses the cellular toxicity of misfolded proteins by promoting their degradation through the ubiquitin-proteasome system. Hum. Mol. Genet., 18, 688-700.
37. Ganesh, S., Delgado-Escueta, A.V., Suzuki, T., Francheschetti, S., Riggio, C., Avanzini, G., Rabinowicz, A., Bohlega, S., Bailey, J., Alonso, M.E. et al. (2002) Genotype-phenotype correlations for EPM2A mutations in Lafora's progressive myoclonus epilepsy: Exon 1 mutations associate with an early-onset cognitive deficit subphenotype. Hum. Mol. Genet., 11, 1263-1271.